BACKGROUND: Oral reactivation of latent Herpes simplex virus (HSV) infection may easily occur in cancer patients. Virus reactivation can cause oral mucosa damage, worsen already existing lesions caused by stomatotoxic effect of cancer therapy and, whether symptomatic or asymptomatic, ample spreading and promote viral transmission. METHODS: Polymerase chain reaction (PCR), cell-culture and direct immunofluorescence have been used to determine the frequency of oral HSV reactivation in 60 patients undergoing chemotherapy for different malignancies. RESULTS: By means of PCR, the presence of viral DNA was detected in 71.7% of patients prior to chemotherapy and in 85.0% after chemotherapy. 33.3% of patients before and 40.0% after chemotherapy were viral-culture positive, while 3.3% of patients before and 11.7% after chemotherapy were positive as shown by direct immunofluorescence. No significant difference in HSV-1 reactivation was found before and after chemotherapy. In addition, no significant difference was found when comparing HSV-1 reactivation in patients with and without mucositis. HSV-2 was not detected in any of the patients. CONCLUSIONS: Reactivation of latent HSV is exceptionally frequent in cancer patients. The results of this study suggest that virus reactivation occurs independently of cancer chemotherapy. The potential role of HSV reactivation in oral mucosa damage remains unclear.
BACKGROUND: Oral reactivation of latent Herpes simplex virus (HSV) infection may easily occur in cancerpatients. Virus reactivation can cause oral mucosa damage, worsen already existing lesions caused by stomatotoxic effect of cancer therapy and, whether symptomatic or asymptomatic, ample spreading and promote viral transmission. METHODS: Polymerase chain reaction (PCR), cell-culture and direct immunofluorescence have been used to determine the frequency of oral HSV reactivation in 60 patients undergoing chemotherapy for different malignancies. RESULTS: By means of PCR, the presence of viral DNA was detected in 71.7% of patients prior to chemotherapy and in 85.0% after chemotherapy. 33.3% of patients before and 40.0% after chemotherapy were viral-culture positive, while 3.3% of patients before and 11.7% after chemotherapy were positive as shown by direct immunofluorescence. No significant difference in HSV-1 reactivation was found before and after chemotherapy. In addition, no significant difference was found when comparing HSV-1 reactivation in patients with and without mucositis. HSV-2 was not detected in any of the patients. CONCLUSIONS: Reactivation of latent HSV is exceptionally frequent in cancerpatients. The results of this study suggest that virus reactivation occurs independently of cancer chemotherapy. The potential role of HSV reactivation in oral mucosa damage remains unclear.
Authors: Alexander Kofman; Lucasz Marcinkiewicz; Evan Dupart; Anton Lyshchev; Boris Martynov; Anatolii Ryndin; Elena Kotelevskaya; Jay Brown; David Schiff; Roger Abounader Journal: J Neurooncol Date: 2011-07-01 Impact factor: 4.130
Authors: Sharon Elad; Vinisha Ranna; Anura Ariyawardana; Maria Elvira Pizzigatti Correa; Vanessa Tilly; Raj G Nair; Tanya Rouleau; Richard M Logan; Andres Pinto; Veronica Charette; Debbie P Saunders; Siri Beier Jensen Journal: Support Care Cancer Date: 2016-11-16 Impact factor: 3.603
Authors: Sharon Elad; Yehuda Zadik; Ian Hewson; Allan Hovan; M Elvira P Correa; Richard Logan; Linda S Elting; Fred K L Spijkervet; Michael T Brennan Journal: Support Care Cancer Date: 2010-06-11 Impact factor: 3.603
Authors: Ritu Aggarwal; Deepak Bansal; Jasmine Naru; Manila Salaria; Anita Rana; Ranjana W Minz; Amita Trehan; R K Marwaha Journal: Support Care Cancer Date: 2014-02-14 Impact factor: 3.603
Authors: T M Haverman; J E Raber-Durlacher; W M H Rademacher; S Vokurka; J B Epstein; C Huisman; M D Hazenberg; J J de Soet; J de Lange; F R Rozema Journal: Mediators Inflamm Date: 2014-04-10 Impact factor: 4.711